PharmaShots Weekly Snapshot (Oct 26 – 30, 2020)

 PharmaShots Weekly Snapshot (Oct 26 – 30, 2020)

PharmaShots Weekly Snapshot (Oct 26 – 30, 2020)

GSK’s Zejula (niraparib) Receives EC’s Approval as a Treatment in Advanced Ovarian Cancer

Published: Oct 30, 2020 | Tags: Advanced, Approval, Cancer, EU, GSK, Niraparib, Ovarian, Receives, Treatment, Zejula

AbbVie Reports Results of SKYRIZI (risankizumab) in P-III LIMMitless Study in Patients with Moderate to Severe Plaque Psoriasis

Published: Oct 30,2020 | Tags: AbbVie, LIMMitless, Moderate, P-III, patients, Plaque, Psoriasis, Reports, Results, Risankizumab, Severe, Skyrizi, Study

Sanofi Entered into an Agreement with Merck to Conduct a P-II Study of THOR-707 in Sequenced Administration with MSD’s KEYTRUDA® (pembrolizumab) in Patients with Various Cancers

Published: Oct 30, 2020 | Tags: Agreement, Cancers, Clinical Trials, KEYTRUDA, MSD, P-II Study, Sanofi, THOR-707

AstraZenca Reports Results of Fasenra (benralizumab) in P-lllb PONENTE Trial for Asthma

Published: Oct 30, 2020 | Tags: Asthma, AstraZenca, Benralizumab, Fasenra, P-lllb, PONENTE, Trial, Report, Results

Roche’s Tecentriq in Combination with Avastin Receives China NMPA’s Approval for the Treatment of Unresectable Hepatocellular Carcinoma

Published: Oct 30,2020 | Tags: approval, Avastin, IMbrave150, NMPA, Roche, Sorafenib, Tecentriq, Unresectable Hepatocellular Carcinoma

AstraZenca Expands Supply Agreement with Cheplapharm for Atacand (candesartan cilexetil) and Atacand Plus (candesartan cilexetil + hydrochlorothiazide) to Cheplapharm

Published: Oct 30,2020 | Tags: AstraZenca, Atacand, Atacand Plus, Candesartan cilexetil, Candesartan, cilexetil + Hydrochlorothiazide, Cheplapharm, Expands, Supply Agreement

CStone Signs a License Agreement with LegoChem for LCB71 to Treat Multiple Cancer Indications

Published: Oct 29,2020 | Tags: CStone, LegoChem, License Agreement, New Antibody Drug, Signs

Novartis Acquires Vedere Bio for $280M

Published: Oct 29,2020 | Tags: $280M, Acquire, Novartis, Vedere Bio

BMS Signs a Five-Year Agreement with Insitro to Develop Therapies for ALS and Frontotemporal Dementia

Published: Oct 29,2020 | Tags: Agreement, ALS, BMS, Develop, Five-Year, Frontotemporal Dementia, Insitro, Signs, Therapies

Boehringer Ingelheim Initiates P-II Study of BI 764198 for Patients with Severe Respiratory Illness from COVID-19

Published: Oct 29,2020 | Tags: Boehringer Ingelheim, Clinical, COVID-19, Illness, Initiates, P-II, People, Respiratory, Severe, Targeted, Therapy, Trial

Lilly Reports Results of Bamlanivimab (LY-CoV555) in P-II BLAZE-1 Study in New England Journal of Medicine

Published: Oct 29,2020 | Tags: Bamlanivimab, BLAZE-1, Lilly, LY-CoV555, New England Journal of Medicine, P-II, Reports, Results, Study

Regeneron Reports Results of REGN-COV2 in P-ll/lll Study in Patients with COVID-19 in Outpatient Setting

Published: Oct 29,2020 | Tags: COVID-19, P-ll/lll Trial, Regeneron, REGN-COV2, REGN10933 + REGN10987, Reports, Results

Dermavant Presents Results of Tapinarof in Pivotal P-III PSOARING Program at the 29th EADV Virtual Congress

Published: Oct 28,2020 | Tags: Cream, Data, Dermavant, EADV, P-III, Pivotal, Presents, PSOARING, Results, Tapinarof

Thermo Fisher Expands its Direct-to-Patient Service Offerings

Published: Oct 28, 2020 | Tags: Clinical, Direct, Expand, Offerings, Patient, Service, Thermo Fisher, Trials

Exact Sciences to Acquire Thrive Earlier Detection for ~$2.15B

Published: Oct 28, 2020 | Tags: ~$2.15B, Acquire, Exact Sciences, Thrive Earlier Detection

Sanofi Presents Results of Olipudase Alfa in Two Clinical Studies at ASHG 2020

Published: Oct 28,2020 | Tags: ASMD, Function, Improvement, Lung, Olipudase alfa, Patients, Reports, Results, Sanofi, Spleen, Volume

Novartis Signs an Option and License Agreement with Molecular Partners to Develop Two DARPin Therapies for COVID-19

Published: Oct 28,2020 | Tags: COVID-19, DARPin Therapies, Develop, License Agreement, Molecular Partners, Novartis, Option, Signs, Two

AstraZeneca’s Forxiga (dapagliflozin) Receive NMPA’s Approval for Label Update to Include Data of P-III DECLARE-TIMI 58 Study

Published: Oct 28, 2020 | Tags: Approval, AstraZeneca, Dapagliflozin, DECLARE-TIMI, 58 Forxiga, Include, Label, NMPA, P-III, Receives, Results, Trial, Update

Samsung Bioepis Reports Results of Renflexis (biosimilar, infliximab) from Two Studies in IBD Patients

Published: Oct 27, 2020 | Tags: 2020, ACG, Affairs, Healthcare, IBD, infliximab-abda, patients, RENFLEXIS, Reports, Results, Samsung Bioepis, Studies, System, Two, Veterans

Medtronic’s Abre Venous Stent Receives the US FDA’s Approval to Treat Venous Outflow Obstruction

Published: Oct 27,2020 | Tags: approval, Medtronic, Obstruction, Outflow, Receives, Stent, Treat, US FDA, Venous

Novartis Presents Results of Iptacopan (LNP023) in P-ll Study for C3 Glomerulopathy at ASN Annual Meeting 2020

Published: Oct 27, 2020 | Tags: ASN Annual Meeting 2020, C3 Glomerulopathy (C3G), Iptacopan, Novartis, P-ll Study, Result

Sanofi and Regeneron Report Results of Dupixent (dupilumab) in Part A of P-lll Study for Eosinophilic Esophagitis (EoE)

Published: Oct 27, 2020 | Tags: dupilumab, Dupixent, EoE, P-lll Study, Regeneron, Reports, Results, Virtual ACG 2020 and UEG Week 2020

CStone Signs an Out-Licensing Agreement with EQRx for Sugemalimab and CS1003

Published: Oct 27, 2020 | Tags: CS1003 (anti-PD-1), CStone, EQRx, Out-Licensing Agreement, Signs, Sugemalimab (anti-PD-L1), Targeted Indication

Jazz Pharmaceuticals Acquires SpringWorks’ FAAH Inhibitor Program for Post-Traumatic Stress Disorder

Published: Oct 27,2020 | Tags: Acquires, FAAH Inhibitor Program, Jazz Pharmaceutical, SpringWorks Therapeutics

AstraZeneca Presents Results of Farxiga (dapagliflozin) in P-lll DAPA-CKD Study for Chronic Kidney Disease at ASN Kidney Week 2020

Published: Oct 26,2020 | Tags: AstraZeneca, CKD, DAPA-CKD Study, Dapagliflozin, Farxiga, P-lll, Result

Boehringer Ingelheim and Eli Lilly Report Results of Jardiance in Adults with HFrEF Regardless of Chronic Kidney Disease Status

Published: Oct 26,2020 | Tags: Adults, Boehringer Ingelheim, Chronic Disease, Eli Lilly, HFrEF, Jardiance, Kidney, Regardless, Reports, Results, Status

AstraZeneca Resumes P-III Study of AZD1222 Against COVID-19 in the US

Published: Oct 26,2020 | Tags: Against, AstraZeneca, AZD1222, COVID-19, P-III, Resumes, Study, US

Eisai and Cogstate Expand their Agreement to Develop and Commercialize Digital Cognitive Assessment Technologies

Published: Oct 26,2020 | Tags: Agreement, Cogstate, Digital Cognitive Assessment Technologies, Eisai, Expand

Bayer Acquires Asklepios for ~$4B

Published: Oct 26, 2020 | Tags: (AskBio), ~$4B, Acquires, Asklepios BioPharmaceutical, Bayer

Foundation Medicine’s FoundationOne CDx Receives the US FDA’s Approval as a CDx for Vitrakvi (larotrectinib)

Published: Oct 26, 2020 | Tags: Across, ALL, approval, Companion, Diagnostic, Foundation Medicine, FoundationOne CDx, Fusions, Identify, Larotrectinib, NTRK, Patients, Receives, Solid, Tumors, U.S.FDA, Vitrakvi

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post